The relationship between concentration of specific antibody at birth and subsequent response to primary immunization

Vaccine

Volumn 32, Issue 8, 2014, Pages 996-1002

  Jones, Christine ^a,c   Pollock, Louisa ^b,d   Barnett, Sara M ^a   Battersby, Anna ^a,b   Kampmann, Beate ^a,b  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b MEDICAL RESEARCH COUNCIL LABORATORIES   (Gambia)

^c ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^d UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

Immune response; Infant; Vaccine

Indexed keywords

BACTERIUM ANTIBODY; BORDETELLA PERTUSSIS ANTIBODY; HAEMOPHILUS INFLUENZAE TYPE B ANTIBODY; PNEUMOCOCCAL ANTIBODY; TETANUS ANTIBODY; UNCLASSIFIED DRUG;

ANTIBODY BLOOD LEVEL; ANTIBODY RESPONSE; ARTICLE; BIRTH; BLOOD; BORDETELLA PERTUSSIS; COMPARATIVE STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; HAEMOPHILUS INFLUENZAE TYPE B; HUMAN; IMMUNE RESPONSE; IMMUNIZATION; INFANT; MALE; PERTUSSIS; PRIORITY JOURNAL; PROTECTION; STREPTOCOCCUS PNEUMONIAE; TETANUS; UNITED KINGDOM;

IMMUNE RESPONSE; INFANT; VACCINE;

ADULT; ANTIBODIES, BACTERIAL; DIPHTHERIA-TETANUS-PERTUSSIS VACCINE; FEMALE; HAEMOPHILUS INFECTIONS; HAEMOPHILUS VACCINES; HUMANS; IMMUNITY, HUMORAL; IMMUNITY, MATERNALLY-ACQUIRED; INFANT; INFANT, NEWBORN; MALE; PNEUMOCOCCAL INFECTIONS; PNEUMOCOCCAL VACCINES; TETANUS; TETANUS TOXOID; WHOOPING COUGH;

EID: 84892996311     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2013.11.104     Document Type: Article

References (39)

1. Albrecht P., Ennis F.A., Saltzman E.J., Krugman S. Persistence of maternal antibody in infants beyond 12 months: mechanism of measles vaccine failure. The Journal of Pediatrics 1977, 91(5):715-718.
2. Leuridan E., Van Damme P. Passive transmission and persistence of naturally acquired or vaccine-induced maternal antibodies against measles in newborns. Vaccine 2007, 25(34):6296-6304.
3. Kim D., Huey D., Oglesbee M., Niewiesk S. Insights into the regulatory mechanism controlling the inhibition of vaccine-induced seroconversion by maternal antibodies. Blood 2011, 117(23):6143-6151.
4. Factors affecting the immunogenicity of oral poliovirus vaccine: a prospective evaluation in Brazil and the Gambia. World Health Organization Collaborative Study Group on Oral Poliovirus Vaccine. The Journal of Infectious Diseases 1995, 171(5):1097-1106.
5. Gans H., Yasukawa L., Rinki M., DeHovitz R., Forghani B., Beeler J., et al. Immune responses to measles and mumps vaccination of infants at 6, 9, and 12 months. The Journal of Infectious Diseases 2001, 184(7):817-826.
6. Klinge J., Lugauer S., Korn K., Heininger U., Stehr K. Comparison of immunogenicity and reactogenicity of a measles, mumps and rubella (MMR) vaccine in German children vaccinated at 9-11, 12-14 or 15-17 months of age. Vaccine 2000, 18(27):3134-3140.
7. Burstyn D.G., Baraff L.J., Peppler M.S., Leake R.D., St Geme J., Manclark C.R. Serological response to filamentous hemagglutinin and lymphocytosis-promoting toxin of Bordetella pertussis. Infection and Immunity 1983, 41(3):1150-1156.
8. Belloni C., De Silvestri A., Tinelli C., Avanzini M.A., Marconi M., Strano F., et al. Immunogenicity of a three-component acellular pertussis vaccine administered at birth. Pediatrics 2003, 111(5 Pt 1):1042-1045.
9. Van Savage J., Decker M.D., Edwards K.M., Sell S.H., Karzon D.T. Natural history of pertussis antibody in the infant and effect on vaccine response. The Journal of Infectious Diseases 1990, 161(3):487-492.
10. Englund J.A., Anderson E.L., Reed G.F., Decker M.D., Edwards K.M., Pichichero M.E., et al. The effect of maternal antibody on the serologic response and the incidence of adverse reactions after primary immunization with acellular and whole-cell pertussis vaccines combined with diphtheria and tetanus toxoids. Pediatrics 1995, 96(3 Pt 2):580-584.
11. Booy R., Aitken S.J., Taylor S., Tudor-Williams G., Macfarlane J.A., Moxon E.R., et al. Immunogenicity of combined diphtheria, tetanus, and pertussis vaccine given at 2, 3, and 4 months versus 3, 5, and 9 months of age. Lancet 1992, 339(8792):507-510.
12. Wang Z., Zhang S., Luo C., Wu Q., Liu Q., Zhou Y.H., et al. Transplacentally acquired maternal antibody against hepatitis B surface antigen in infants and its influence on the response to hepatitis B vaccine. PLoS ONE 2011, 6(9):e25130.
13. Siegrist C.A., Cordova M., Brandt C., Barrios C., Berney M., Tougne C., et al. Determinants of infant responses to vaccines in presence of maternal antibodies. Vaccine 1998, 16(14-15):1409-1414.
14. Kuehn B.M. ACIP. give pertussis vaccine during every pregnancy. JAMA: The Journal of the American Medical Association 2012, 308(19):1960.
15. Joint Committee on Vaccination and Immunisation Minutes of Teleconference on Pertussis 2012.
16. Jones C., Pollock L., Barnett S.M., Battersby A., Kampmann B. Specific antibodies against vaccine-preventable infections: a mother-infant cohort study. BMJ Open 2013, 3:e002473.
17. Guiso N., Berbers G., Fry N.K., He Q., Riffelmann M., Wirsing von Konig C.H. What to do and what not to do in serological diagnosis of pertussis: recommendations from EU reference laboratories. European Journal of Clinical Microbiology & Infectious Diseases: Official Publication of the European Society of Clinical Microbiology 2011, 30(3):307-312.
18. Tetanus vaccine. Relevé épidémiologique hebdomadaire/Section d'hygiene du Secretariat de la Societe des Nations=Weekly epidemiological record/Health Section of the Secretariat of the League of Nations. Weekly Epidemiological Record 2006, 81(20):197-208.
19. Kayhty H., Peltola H., Karanko V., Makela P.H. The protective level of serum antibodies to the capsular polysaccharide of Haemophilus influenzae type b. The Journal of Infectious Diseases 1983, 147(6):1100.
20. Agbarakwe A.E., Griffiths H., Begg N., Chapel H.M. Avidity of specific IgG antibodies elicited by immunisation against Haemophilus influenzae type b. Journal of Clinical Pathology 1995, 48(3):206-209.
21. Cherry J.D., Gornbein J., Heininger U., Stehr K. A search for serologic correlates of immunity to Bordetella pertussis cough illnesses. Vaccine 1998, 16(20):1901-1906.
22. Storsaeter J., Hallander H.O., Gustafsson L., Olin P. Levels of anti-pertussis antibodies related to protection after household exposure to Bordetella pertussis. Vaccine 1998, 16(20):1907-1916.
23. Taranger J., Trollfors B., Lagergard T., Sundh V., Bryla D.A., Schneerson R., et al. Correlation between pertussis toxin IgG antibodies in postvaccination sera and subsequent protection against pertussis. The Journal of Infectious Diseases 2000, 181(3):1010-1013.
24. Storsaeter J., Hallander H.O., Gustafsson L., Olin P. Low levels of antipertussis antibodies plus lack of history of pertussis correlate with susceptibility after household exposure to Bordetella pertussis. Vaccine 2003, 21(25-26):3542-3549.
25. Gall S.A., Myers J., Pichichero M. Maternal immunization with tetanus-diphtheria-pertussis vaccine: effect on maternal and neonatal serum antibody levels. American Journal of Obstetrics and Gynecology 2011, 204(4):334e1-334e5.
26. Englund J.A., Glezen W.P. Maternal immunization with Haemophilus influenzae type b vaccines in different populations. Vaccine 2003, 21(24):3455-3459.
27. Sarvas H., Kurikka S., Seppala I.J., Makela P.H., Makela O. Maternal antibodies partly inhibit an active antibody response to routine tetanus toxoid immunization in infants. The Journal of Infectious Diseases 1992, 165(5):977-979.
28. Nohynek H., Gustafsson L., Capeding M.R., Kayhty H., Olander R.M., Pascualk L., et al. Effect of transplacentally acquired tetanus antibodies on the antibody responses to Haemophilus influenzae type b-tetanus toxoid conjugate and tetanus toxoid vaccines in Filipino infants. The Pediatric Infectious Disease Journal 1999, 18(1):25-30.
29. O'Brien K.L., Moisi J., Moulton L.H., Madore D., Eick A., Reid R., et al. Predictors of pneumococcal conjugate vaccine immunogenicity among infants and toddlers in an American Indian PnCRM7 efficacy trial. The Journal of Infectious Diseases 2007, 196(1):104-114.
30. Siegrist C.A. Mechanisms by which maternal antibodies influence infant vaccine responses: review of hypotheses and definition of main determinants. Vaccine 2003, 21(24):3406-3412.
31. Pritchard J.A. Blood volume changes in pregnancy and the puerperium. IV. Anemia associated with hydatidiform mole. American Journal of Obstetrics and Gynecology 1965, 91:621-629.
32. Amino N., Tanizawa O., Miyai K., Tanaka F., Hayashi C., Kawashima M., et al. Changes of serum immunoglobulins IgG, IgA, IgM, and IgE during pregnancy. Obstetrics and Gynecology 1978, 52(4):415-420.
33. Abel J., Conklin J., Hunter S., Empey R., Tyler E., Christensen A., et al. Defining normal IgG changes throughout pregnancy. Proceedings in Obstetrics and Gynaecology 2013, 3(2):8.
34. Palmeira P., Quinello C., Silveira-Lessa A.L., Zago C.A., Carneiro-Sampaio M. IgG placental transfer in healthy and pathological pregnancies. Clinical & Developmental Immunology 2012, 2012:985646.
35. Jones C.E., Naidoo S., De Beer C., Esser M., Kampmann B., Hesseling A.C. Maternal HIV infection and antibody responses against vaccine-preventable diseases in uninfected infants. JAMA: The Journal of the American Medical Association 2011, 305(6):576-584.
36. Campbell H., Amirthalingam G., Andrews N., Fry N.K., George R.C., Harrison T.G., et al. Accelerating control of pertussis in England and Wales. Emerging Infectious Diseases 2012, 18(1):38-47.
37. Beyer W.E., Palache A.M., Luchters G., Nauta J., Osterhaus A.D. Seroprotection rate, mean fold increase, seroconversion rate: which parameter adequately expresses seroresponse to influenza vaccinationα. Virus Research 2004, 103(1/2):125-132.
38. Plikaytis B.D., Carlone G.M. Statistical considerations for vaccine immunogenicity trials. Part 2. Noninferiority and other statistical approaches to vaccine evaluation. Vaccine 2005, 23(13):1606-1614.
39. Blanchard-Rohner G., Watt H., Kelly D.F., Yu L.M., Snape M.D., Pollard A.J. Baseline polysaccharide-specific antibodies may not consistently inhibit booster antibody responses in infants to a serogroup C meningococcal protein-polysaccharide conjugate vaccine. Vaccine 2012, 30(28):4153-4159.